Compare KOPN & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KOPN | VTGN |
|---|---|---|
| Founded | 1984 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 396.8M | 10.8M |
| IPO Year | 2025 | 2014 |
| Metric | KOPN | VTGN |
|---|---|---|
| Price | $5.00 | $0.27 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 3 |
| Target Price | ★ $4.69 | $0.90 |
| AVG Volume (30 Days) | 2.9M | ★ 18.2M |
| Earning Date | 05-12-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 103.03 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,530,311.00 | N/A |
| Revenue This Year | $50.07 | $124.49 |
| Revenue Next Year | $33.33 | $353.99 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 46.53 | N/A |
| 52 Week Low | $1.81 | $0.20 |
| 52 Week High | $6.61 | $5.14 |
| Indicator | KOPN | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 59.92 | 51.92 |
| Support Level | $4.14 | $0.22 |
| Resistance Level | $5.53 | $0.32 |
| Average True Range (ATR) | 0.24 | 0.03 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 89.16 | 13.72 |
Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.